2727114-26-1
2727114-26-1
Chemical Structure
Biological Activity: Elritercept (KER-050) is a modified activin type IIA receptor ligand trap. Elritercept binds to and neutralizes TGF-β superfamily ligands, including TGF-β, activins (activins), GDF8, GDF11 , and GDFs, blocking ActRIIa-mediated signaling, inhibiting SMAD2/3 signaling, and rebalancing signaling. Elritercept can be used in research on myelodysplastic syndromes, myelofibrosis, MDS/MF-associated anemia, and acute myeloid leukemia[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Elritercept | 97.868% | Elritercept (KER-050) is a modified activin type IIA receptor ligand trap. Elritercept binds to and neutralizes TGF-β superfamily ligands, including TGF-β, activins (activins), GDF8, GDF11 , and GDFs, blocking ActRIIa-mediated signaling, inhibiting SMAD2/3 signaling, and rebalancing signaling. Elritercept can be used in research on myelodysplastic syndromes, myelofibrosis, MDS/MF-associated anemia, and acute myeloid leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moses B, et al. Activin a Inhibition Impaired Human AML Cell Engraftment and Extended Survival in Immunodeficient Mice. Blood. 2024;144(Suppl 1):5658.
- [2]. Bearss MP, et al. MDS-827: Allosteric NEK7 Inhibition With Ofirnoflast (HT-6184) Suppresses Mitochondrial Stress, Reduces Systemic Inflammatory Cytokines, and Attenuates Clonal Expansion in Lower-Risk Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia. 2026 Aug 1;26:S726-7.
- [3]. Gangat N, et al. Targeting anemia in myeloid neoplasms. American journal of hematology. 2024 Sep;99(9):1663-1666.
- [4]. Al Noumani I, et al. Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors. Expert Opinion on Pharmacotherapy. 2026 May 24;27(8):657-68.
- [5]. Myneni VD, et al. Rker-050, a Modified Activin Receptor Type IIa Ligand Trap, Regulates Osteogenic Lineage, Complementing the Erythroid Response and Rebalancing the Osteo-Hematopoietic Niche. Blood. 2024;144(Suppl 1):5660.
